Notch signalling is an evolutionarily conserved multifaceted pathway that controls diverse cellular processes. Its role in regulating development and tissue homeostasis is well established. Aberrant activation of the Notch pathway has been implicated in the initiation and progression of many types of cancers. However, although in some cancers Notch signalling acts as a tumour-promoter, in others it is reported to suppress tumour growth and progression. Accumulating evidence suggests the involvement of both the innate and adaptive immune system in the development of various tumours. Currently, extensive studies on investigating the effects of Notch signalling in tumour immune surveillance are being carried out.
| INTRODUCTION
Notch signalling is an evolutionarily conserved pathway that plays a critical role in regulating cell fate and tissue homeostasis by maintaining a balance between cell proliferation, differentiation and apoptosis. It apparently controls diverse processes like determining cell fate decisions during development, to stem cell-renewal and also differentiation in a wide array of adult tissues. [1] [2] [3] Notch signalling depicts a paracrine model of communication, which is mediated by Notch ligand-receptor interactions between neighbouring cells. In mammals, there are four trans membrane receptors (Notch 1, 2, 3, 4) that are recognized by five ligands viz Delta-like ligands (DLL)-1, 3, 4 and Jagged-1 and 2. 4 Engagement of Notch with their ligands brings about receptor conformational changes that results in the cleavage of Notch intracellular domain (NICD) by gsecretase leading to the release of NICD and its translocation into the nucleus where it interacts with various transcription factors such as recombination signal binding protein for immunoglobulin kJ region (RBP-Jk) unleashing the so-called "canonical" signalling pathway. On the other hand, recent studies reveal the existence of several other modes of Notch signalling generally referred to as noncanonical Notch signalling. 4 Non-canonical signalling may occur in the absence of receptor cleavage or through NICD driven transcription via NF-kB, PI3K, mTORC2, Akt and β-catenin.
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The complex network of Notch, tumour cells, the tumour microenvironment and immune system seems to coordinate the progression and outcome of cancer and might represent potential targets for customised cancer therapies. In this review, we will particularly examine the state of the art concerning the interaction of Notch signalling with different types of immune cells in regulation of tumour immune responses.
| IMPORTANCE OF NOTCH SIGNALLING
Deregulation of Notch signalling has been implicated in many pathological processes, including cancer and various hematologic malignancies. 6 In fact, Notch and NF B are the two pathways that are strongly interconnected in tumour development. NF-B subunits have been identified as potential nuclear binding partners of intracellular Notch proteins. Different Notch receptors execute their functioning through diverse mechanisms. For instance, Notch 1 causes cell cycle arrest followed by apoptosis possibly through a p53-dependent reduction in Bcl-2 pathway. 7 On the other hand, Notch 3 is involved in controlling the differentiation and spread of HCC. 8 Notch1 signalling mediates hypoxia/HIF-1α production, which in turn promotes cell proliferation, invasion and chemoresistance in T cell acute lymphoblastic leukaemia (T-ALL). 9 Notch signalling is also involved in epithelial to mesenchymal transition during tumour progression and metastasis. 10 Inhibition of Notch signalling often enhances the chemosensitivity of many tumours. 11, 12 Further, clinical findings suggest that Notch signalling impacts survival in human cancers. [13] [14] [15] It was reported that Inhibition of γ-secretase does not block all Notch-related functions in tumour cells, thereby indicating the functionality of non-canonical Notch signalling in transformed cells. [16] [17] [18] Interestingly, Notch pathway can act as both tumour suppressor and tumour-promoter. For instance, it causes growth arrest by suppressing SIRT1 and activating p53 in Ewing sarcoma, which is also implicated in B cell tumours and human keratinocytes.
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Earlier reports emphasized the role of Notch signalling in tumour onset and progression. However, recent studies highlight its crucial involvement in the crosstalk between tumour cells and their microenvironment. Additionally, it has been demonstrated that Notch is an integral part of haematopoietic stem cell development and influences the multiple lineage decisions of developing lymphoid and myeloid cells. 2, 20 Since any defect in immune cell lineages will have direct consequences on tumour immune microenvironment, different groups have analysed the perturbation of regulatory immune networks and immune surveillance in anti-tumour immunity.
| IMMUNE SURVEILLANCE IN TUMOUR MICROENVIRONMENT
Tumour development is a multi-step process involving the expansion of a single transformed cell to a clone of tumour-forming malignant cells. 21, 22 To achieve this, the tumour microenvironment within a tissue is continuously modified in the course of tumour development so as to meet its requirements and sustain its growth. Cells of the haematopoietic system, lymphocytes, macrophages and granulocytes are frequently found surrounding the tumour. The immune system can either block tumour development or induce carcinogenesis through the course of tumour progression. 23 The role of immune system in these conditions depends on the balance of pro-and anti-tumour responses by both innate and adaptive immunity. 24 While the presence of the immune cells in the tumour microenvironment has been generally taken as a sign that the tumour is not ignored by the host immune system, it is important to note that the earliest stages of tumour progression that is hyperplasia and dysplasia, appear to escape from the immune system. 25, 26 There may be at least two explanations for this lack of the visible involvement of immune cells in the earliest phase of tumour growth: (a) the genetic modification in the tumour cell does not result in the phenotypic change at its surface and remains ªsilent°or (b) the genetic change is noted, the immune response is made and the genetically unstable tumour under immune pressure develops immuneresistant variants, the phenomenon referred to as "immune selection" Or immune editing.
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Eventually once a tumour is formed, it perpetuates by evading the immune response. This is often attributed to pre-established tolerance developed from non-recognition of tumour antigens 27 or generation of less immunogenic tumour cell sub-clones or release of immunosuppressor molecules like cytokines and hormones which suppress NK and T cell in the tumour microenvironment. 28 
| NOTCH SIGNALLING IN TUMOUR IMMUNE SURVEILLANCE
The Notch signalling pathway has recently emerged as a key player in the development and functioning of the immune cells. Fate of notch signalling decided by their receptor expressed by the cells. Earlier, Notch was considered to be vital in determining the cell-lineage commitment in developing lymphocytes regulation of their corresponding immune responses ( Figure 1 ) [29] [30] [31] but is now also known to regulate the homeostasis of a number of innate cell types. 32, 33 The precise amount of notch activity is crucial in regulating the different immune cell function (Figure 2) . The first indication for involvement of Notch pathway in oncogenesis came from the studies in T cell acute lymphoblastic leukaemia (T-ALL). 34, 35 Here in chromosomal translocation of Notch1 gene was identified as a cause of T cell oncogenesis. Subsequent reports, associated Notch pathway with tumorigenesis and cancer progression in other solid tumours as well, including breast, ovarian, cervical, lung, prostate carcinomas, gliomas and mesotheliomas. 17, [34] [35] [36] [37] [38] It is well documented that Notch signalling regulates proliferation, differentiation and survival of immune and tumour cells both 15, 39 and also maintain the stem cell-like characteristics in cancer stem cells. [40] [41] [42] However, in addition to its role in tumorigenesis, Notch has also been reported to act as a tumour suppressor in certain cell types such as skin epithelium. 43, 44 Tumour cells are often surrounded by tumour-infiltrating lymphocytes (TILs) and despite the presence of immune cells in the tumour microenvironment, the tumour grows progressively and metastasizes, largely because it evolves strategies to escape the immune surveillance. 45 Different studies revealed that notch signalling is decreased in haematopoietic immune cells resulting in inadequate induction of anti-tumour immunity in cancer patients. 46 Since, Notch signalling plays a crucial role in the development and functioning of most of the immune cells types, which are also present in the tumour microenvironment, it would be relevant to understand its function in relation to the major immune players of tumour microenvironment ( Figure 3 ). 
| NOTCH MEDIATED IMMUNE SURVEILLANCE THROUGH LYMPHOCYTES
Tumours are often infiltrated with various lymphocytes including NK cells, macrophages, DCs, T cells and B cells. 47 Notch signalling has recently been implicated in the development and functioning of these immune cells. Earlier, Notch was considered to be vital in determining the cell-lineage commitment in developing lymphocytes, [29] [30] [31] but is now also known to control the homeostasis of a number of innate cell subsets. 32, 33 Moreover, the involvement of Notch in adaptive immunity has become prominent in regulating the differentiation and functioning of T cells. 48 More recently, a prominent role of Notch has emerged in controlling dendritic cell (DC) homeostasis 49, 50 and in the development of several lymphocyte populations of the innate immune system. 53 However, recently it was observed that two major subsets of DCs: myeloid DCs, differentiated from myeloid progenitors in bone marrow and small proportion of DCs differentiated from lymphoid progenitors are directly controlled by notch signalling receptors and ligands. 54 Weijzen et al showed that Jagged-1 could induce maturation of monocyte-derived human dendritic cells. 55 However, few controversial reports demonstrated that active Notch-1 enhanced the stem cell compartment but inhibited the myeloid cell differentiation. 56 Recent studies have also pointed out that tumours increase the secretion of factors that hinder the DC differentiation and functions. Further, It has been observed that notch signalling is not only involved in regulation of DCs differentiation but also plays a pivotal role in activation of DCs, which is essential for tumour immunity. 32 In the colon tumour microenvironment, influence of notch signalling was importantly seen in DC mediated cytotoxic T cells. 57 
| T Cells
Activation of notch regulates Th1, Th2, Th17 and TFh differentiation 58, 59 and is essential for proliferation and effector function of CD4 + and CD8 + T cells. Notch also influences T cell priming and promotes differentiation of naïve CD8 + T cells into memory, cytotoxic and effector T cells. 48 Tumours often repress Notch activity in T lymphocytes to escape from immune surveillance and this T cell repression is generally mediated through induction of PD-1 program death receptor. 57 For instance, Notch-1 and -2 were found to be critical for proliferation and IFN-γ production of activated tumour suppressing CD8 + T cells, whose percentage was significantly decreased in tumour-infiltrating T lymphocyte. Further, blocking the nuclear transport of Notch 2 intracellular domain, inhibited the cytotoxic efficacy of CD8 + T cells in hepatocellular carcinoma. 60 It has also been observed that, cancer induces glucose restriction 
| Macrophages
Macrophages are one of the major and important tumour-infiltrating cells and are known as tumour-associated macrophages (TAMs). While normal macrophages are APCs, which play an important role in control of infections, TAMs are reprogrammed to inhibit lymphocyte functions through release of specific cytokines, prostaglandins or reactive oxygen metabolites (ROM). Macrophages have been shown to exhibit both tumour suppressing and promoting effects, depending on the niche and microenvironment. 66 Notch signalling plays an important role in polarization of macrophages. While M1 macrophages produce pro-inflammatory cytokines to regulate tumour responses, switching polarization to M2 macrophages cause release of anti-inflammatory cytokines, which promote tumour progression. 67 Notch signalling plays an important role in polarization of macrophages. Active Notch signalling polarizes the macrophages towards M1 phenotype, whereas blocking of notch pathway leads to M2-like phenotype. 68, 69 Interestingly, a few studies have highlighted that certain miRNAs under the regulation of Notch signalling, like miR-152a and miR-148a-3p, enhance the activation of pro-inflammatory macrophages. 70 Further, Notch activation can repress signal regulatory protein α (SIRPα), which is a promoter of M2 polarization. 71 Another report showed that Notch is involved indirectly in regulating the expression of a subunit of IL-12 in activated macrophages, which promotes a Th1 type immune response. 72 Targeting the notch signalling may thus provide opportunity to develop new therapies for cancers by the modulation of macrophages.
| NOTCH MEDIATED IMMUNE SURVEILLANCE THROUGH CANCER STEM CELLS (CSCS)
Existence of cancer stem cells and their role in tumour initiation and progression is now being supported by various groups. 73, 74 CSCs are a subpopulation of cancer cells, which have the capability to self-renew as well as to maintain the heterogeneity of tumour mass. In fact, in metastatic cancers, resistance to conventional therapies is often ascribed to the presence of CSCs. CSCs are generally recognized using surface immune markers. However, due to redundant expression of these markers, the precise identification of CSCs is still elusive. 75 Cancer stem cells share a very interesting relationship with the immune cells. On one hand, certain immune cells like TAMs, MDSCs, DCs and Tregs contribute to the maintenance of CSCs and on the other CSCs induce pro-tumorigenic immune cell response and inhibits anti-tumorigenic activities. 76 For instance, tumour-associated macrophages (M2)
help the CSCs to sustain their ability of self-renewal, metastatic potential and chemotherapeutic resistance. [77] [78] [79] CSCs secrete CSF-1, which promotes TAMs to produce EGF that in turn further stimulates the secretion of CSF-1 by CSCs. Different groups have demonstrated that TAMs secrete proinflammatory cytokines like IL-17 and IL-6, to promote selfrenewal of CSCs (Figure 3) . 80 In addition to tumour macrophages, tumour monocytes also upregulate the expression of Sox 2, Oct-4, Nanog and Sca-1 by activating paracrine STAT3 signalling. 81 Conversely, CSCs can promote the polarization of macrophages towards the immunosuppressive M2 phenotype and also induce the expansion of cancer-promoting T regulatory cells (Figure 3 ). 68 Apart from directly driving tumour progression, CSCs also facilitate tumour immune escape. CSCs are less immunogenic and can therefore effectively surpass the antitumour immune response. They show down regulation of MHC-I and lack MHC-II expression, both of which are the potent antigen presenting molecules. 82 Secondly, CSCs can produce immunosuppressive molecules like transforming growth factor beta (TGF-β), IL-10 and IL-13, which help in mitigating the immune system. Colon CSCs were reported to secrete IL-4, which imparted drug resistance and also facilitated the inhibition of anti-tumour immune responses. 83 Notably, certain signalling pathways such as Notch, Wnt and Hedgehog, help in promoting CSC escape. These pathways are highly active in CSCs and are responsible for their self-renewal and uncontrolled proliferation. 84 Further, these pathways also help in promoting tumour-induced KHOSLA ET AL.
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immunosuppression. A recent study showed that Notch1 expression not only inhibited the infiltration of cytotoxic CD8 + T cells and NK cells in melanoma, but also reduced the release of IFN-γ in the tumour tissue. Additionally, it enhanced the inhibition of T cell proliferation and activation, and lead to a significant increase of MDSCs in the tumour microenvironment. 85, 86 Prior to this report Peng et al demonstrated that MDSCs could induce phosphorylation of STAT3 (Figure 3) ,a vital oncogenic mediator and lead to its prolonged activation by inducing nitric oxide (NO) mediated NOTCH signalling. 87 In addition to its important roles in CSCs, Notch signalling is also involved in EMT to promote cancer cell acquisition of a stem-like phenotype and drug resistance. 88 Notch signalling has also merged crucial player in regulation of cytokine secretion by T cells and in immune homeostasis. 86, 87, 89, 90 For instance, prostate cancer cells undergoing EMT displayed stem-like cell features characterized by increased expression of Notch 1 and other pluripotent genes such as Sox2, Nanog, Oct4 and Lin28.
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| NOTCH SIGNALLING AND RECENT DEVELOPMENTS IN THERAPEUTIC APPROACHES
Notch seems to be a promising target for cancer therapy. Notch pathway in CSCs mostly consists of γ-secretase inhibitors and anti-DLL4 antibodies. Inhibition of the Notch pathway via γ-secretase inhibitors prevents notch receptor cleavage at the cell surface, and blocks activation of self-renewal target genes. Currently, γ-secretase inhibitors RO4929097, LY900009 and PF-003084014 are being used in independent clinical studies against breast cancer, ovarian cancer and T cell acute lymphoblastic leukaemia and alzheimer's respectively [93] [94] [95] [96] However, it is evidently reported in rodents that these inhibitors caused abnormalities in the gastrointestinal tract, thymus and spleen. These toxic effects were due to prolonged use of these inhibitors causing malfunctioning in cell fate decisions. 97 Hence, alternative immune therapy targeting extracellular domain of γ-secretase (nicastrin) was proposed to overcome these problems. Inhibition of γ-secretase, and that targeting nicastrin could be a novel therapeutic strategy against cancer caused by aberrant γ-secretase activity and Notch signalling. 98, 99 In addition to γ-secretase inhibitors, monoclonal antibodies targeting DLL4 like Enoticumab (REGN421) and Demcizumab are being clinically tested in advanced ovarian, colon and breast cancer patients with overexpression of DLL4. 100, 101 However, Demcizumab showed hypertension and an increased risk of congestive heart failure as side effects after prolonged drug usage.
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| NOTCH AND INFLAMMATION
Inflammation has dual role, as inflammatory milieu is vital for tumour progression but in few instances inflammation can also protect against cancer. Hes1 mediated Notch signalling inhibits Ppar-y, thereby manifesting autocrine effect and leading to production of IL-6, TNF-α and IL-1β by tumour cells, all of which promote tumour progression strong correlation between specific inflammatory mediators and Notch signalling molecules. High expression levels of Jagged1, Notch 1 and Notch 2 have been known to correlate with tumour progression of myeloma. 105 In conjunction, a recent study reported that jagged ligands from multiple myeloma enhanced tumour growth by increased autocrine and paracrine secretion of interleukin-6 in the bone marrow niche. 106 In a mouse model of pancreatic cancer, the Hes1-mediated suppression of anti-inflammatory nuclear receptor Ppar-γ induced the autocrine production of inflammatory mediators' like TNF-α, IL-6 and IL-1β by pancreatic tumour cells. A role for TNF-α/IKKα in the regulation of Notch1 signalling has also been reported in liver cancer cell lines: it has been proposed that the phosphorylation of FOXA2 (critical gene required for bile acid homeostasis), by IKKα, leads to activation of Notch1 signalling through down regulation of NUMB thereby inducing tumorigenesis 107 ( Figure 4 ).
In tongue squamous cell carcinomas, the IL-1β upregulates CXC chemokine receptor 4 (CXCR4), that mediates cancer growth and metastasis, leading to the concomitant activation of extracellular regulated kinase (ERK); interestingly, the pharmacological inhibition of Notch1 signalling reversed this up-regulation. 108 Cumulatively, these reports suggest that pro-inflammatory stimuli like IL-1β, IL-6, IL-8 and TNF-α can activate Notch signalling, which exerts a tumour-promoting effect on epithelial cells. As mentioned earlier, some records indicate a protective role of Notch signalling in cancer progression 109 wherein inflammation plays a crucial role. For instance Talora and colleagues demonstrated that HPV-positive invasive as well as non-invasive cervical cancers express significantly lower levels of the Notch1. 110 Blocking of NF-kB was shown to trigger invasive human epidermal neoplasia through TNF/JNK activity. 111 Since Notch activation leads to induction of NF-κB 112 it is quite possible that the tumour suppressing function of Notch in this case is mediated by NF-κB. Another evidence supporting the fact that pro-inflammatory factors can drive a tumour-suppressive role of Notch is from a study on endothelium. 113 Specific pro-inflammatory cytokines play a pivotal role in regulating functions of endothelial cells. 114 Although this regulation is not directly linked to tumorigenesis, it is important to note that endothelial cells are extensively involved in angiogenesis. 115 Further, Quillard et al found that inflammatory cytokines TNF-α and IL-1β promote apoptosis of tumour cells by increasing the expression of Notch 2. 116 In an in vitro model of breast cancer Sansone et al demonstrated that IL-6 induced CSC renewal through Notch 3. 117 A similar study showed that a gamma secretase inhibitor, which blocks the Notch signalling, could also attenuate the stem-like phenotype of cancer cells and reduced the T cell-mediated production of both IL-6 and IL-8. Another interesting association of pro-inflammatory cytokine IL-1 with Notch receptors1-4 was reported in breast cancer, where Leptin (a proliferation factor), was the link that promoted cell proliferation and migration through increased expression of pro-angiogenic molecules. 118 
| CONCLUSION
The immune system can exert either protumorigenic or antitumorigenic effects in the development of cancer. Literature reviewed here suggests that CSCs play a vital role in shifting this balance, towards tumour progression. Consequently, understanding the specific interactions between CSCs and the immune system will be essential. Dissecting the molecular mechanisms of CSC-specific immunity can help in developing immunotherapy approaches that eradicate the entire tumour without leaving behind chemoresistant CSCs. Notch is an important pathway which lies at the centre stage of the complex crosstalk between various immune cells and CSCs. Notch signalling not only facilitates the development and functioning of immune cells, but also orchestrates the events in tumour immune surveillance and escape. Additionally, it helps in the maintenance of CSCs. However, due to multifactorial nature of the tumours and the dichotomy of Notch signalling as a tumour-promoter and suppressor, along with its important role in maintaining tissue homeostasis, directly targeting Notch signalling as a generic therapy for cancer is a matter of great concern. In this scenario, only when the molecular mechanisms at the basis of these interactions and its precise functioning in terms of positive or negative regulation of tumorigenesis is clearly defined, then the manipulation of Notch could be a relevant therapeutic strategy. Further, in the current setting it would be rather beneficial to develop a combination therapy that selectively targets Notch as well as the specific immune cells.
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